“This decision will have no impact on the administrative and commercial structure of Roche SpA, which today has over 600 people in the Monza office and in the area. The transition will be transparent and accountable”
published 12/Nov/2015 – aska news
Rome, 12 Nov. (askanews) – The Swiss pharmaceutical group Roche has announced a plan to sell its production site in Segrate, near Milan. A decision, explains the company in a note, which "has become necessary in the context of the review, announced at a global level, of the production network of small molecule drugs, as a consequence of the evolution of its portfolio, based on drugs for therapies targeted, produced in smaller volumes”.
"It was certainly a difficult decision on a global level, which in Italy leaves us bitter considering the commitment made, the resources invested and the work carried out in over 15 years at our site in Segrate", comments Maurizio de Cicco, president and CEO of Roche Spa: "We intend to face this transition in a transparent and responsible way".
“Roche is in contact with several reputable stakeholders who are potentially interested in examining the site acquisition opportunity. The Segrate facility - recalls the company - started business in 1998 and currently employs around 380 people engaged in the production and packaging of solid and drop formulations. In addition to the Segrate site, Roche has also decided to sell the Clarecastle (Ireland), Leganes (Spain) and Florence (USA) facilities and is actively seeking potential buyers for all facilities.
“This decision will have no impact on the administrative and commercial structure of Roche SpA, which today has over 600 people in the Monza office and in the area. Roche has already informed the workers' representatives and the institutions”, concludes Roche.
Related news: Roche: 1200 employees menacés
